These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33813278)

  • 1. Development and validation of dual-cardiotoxicity evaluation method based on analysis of field potential and contractile force of human iPSC-derived cardiomyocytes / multielectrode assay platform.
    Lee SG; Kim J; Oh MS; Ryu B; Kang KR; Baek J; Lee JM; Choi SO; Kim CY; Chung HM
    Biochem Biophys Res Commun; 2021 May; 555():67-73. PubMed ID: 33813278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
    Yang X; Papoian T
    J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
    Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
    SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
    Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
    J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
    Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
    Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity.
    Sharma A; McKeithan WL; Serrano R; Kitani T; Burridge PW; Del Álamo JC; Mercola M; Wu JC
    Nat Protoc; 2018 Dec; 13(12):3018-3041. PubMed ID: 30413796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
    Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
    Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSAHi study: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes -assessment of inter-facility and cells lot-to-lot-variability.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Washio I; Takahashi E; Miyamoto K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Kunimatsu T
    Regul Toxicol Pharmacol; 2016 Jun; 77():75-86. PubMed ID: 26884090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Voltage Sensitive Dye di-4-ANEPPS and Video-Based Contractility Measurements to Assess Drug Effects on Excitation-Contraction Coupling in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Hortigon-Vinagre MP; Zamora V; Burton FL; Smith GL
    J Cardiovasc Pharmacol; 2021 Mar; 77(3):280-290. PubMed ID: 33109927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of media effects on human induced pluripotent stem cell-derived cardiomyocytes in proarrhythmia risk assessment.
    Schocken D; Stohlman J; Vicente J; Chan D; Patel D; Matta MK; Patel V; Brock M; Millard D; Ross J; Strauss DG; Blinova K
    J Pharmacol Toxicol Methods; 2018; 90():39-47. PubMed ID: 29155283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.
    Scott CW; Zhang X; Abi-Gerges N; Lamore SD; Abassi YA; Peters MF
    Toxicol Sci; 2014 Dec; 142(2):331-8. PubMed ID: 25237062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic cardiotoxicity assessment of BMS-986094, a guanosine nucleotide analogue, using human iPS cell-derived cardiomyocytes.
    Yanagida S; Satsuka A; Hayashi S; Ono A; Kanda Y
    J Toxicol Sci; 2021; 46(8):359-369. PubMed ID: 34334557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.
    Dempsey GT; Chaudhary KW; Atwater N; Nguyen C; Brown BS; McNeish JD; Cohen AE; Kralj JM
    J Pharmacol Toxicol Methods; 2016; 81():240-50. PubMed ID: 27184445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
    Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
    J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
    J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.
    Blinova K; Dang Q; Millard D; Smith G; Pierson J; Guo L; Brock M; Lu HR; Kraushaar U; Zeng H; Shi H; Zhang X; Sawada K; Osada T; Kanda Y; Sekino Y; Pang L; Feaster TK; Kettenhofen R; Stockbridge N; Strauss DG; Gintant G
    Cell Rep; 2018 Sep; 24(13):3582-3592. PubMed ID: 30257217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.